ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective
in lowering the amount of HIV in the blood of patients who have been treated with more than 1
protease inhibitor (PI).
Phase:
Phase 2
Details
Lead Sponsor:
ViRx
Treatments:
Efavirenz HIV Protease Inhibitors Lopinavir Protease Inhibitors Ritonavir